安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Tislelizumab Versus Chemotherapy as Second-Line Treatment for . . .
PURPOSEPatients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) have poor prognosis For these patients, treatment options are limited after first-line systemic therapy PATIENTS AND METHODSIn this open-label phase III clinical study,
- Tislelizumab plus chemotherapy versus placebo plus . . .
The options for first-line treatment of advanced oesophageal squamous cell carcinoma are scarce, and the outcomes remain poor The anti-PD-1 antibody, tislelizumab, has shown antitumour activity in previously treated patients with advanced oesophageal squamous cell carcinoma We report interim analysis results from the RATIONALE-306 study, which aimed to assess tislelizumab plus chemotherapy
- Tislelizumab Uses, Side Effects Warnings - Drugs. com
What is tislelizumab? Tislelizumab is used in adults to treat cancer of esophagus that has spread to other parts of the body (metastatic) or cannot be removed with surgery Your doctor will make sure you have correct tumor type to be treated with tislelizumab Tislelizumab may also be used for purposes not listed in this medication guide
- New Treatment Strategies for Esophageal Cancer | Blog | AACR
A study published in the AACR journal Clinical Cancer Research in November 2024 showed that adding tislelizumab to standard-of-care chemotherapy and radiation shrank unresectable esophageal tumors enough to make them eligible for surgical resection, which, in turn, led to longer patient survival
- Tislelizumab efficacy and safety compared to . . . - Frontiers
Tislelizumab efficacy and safety compared to other anti–PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma
- Expanding Options in Esophageal Cancer - Cancer Today
Participants started with the standard treatment of chemoradiation, which is chemotherapy and radiation given at the same time Twenty-four patients had no tumor progression and then received the immunotherapy drug Tevimbra (tislelizumab) and additional chemotherapy
- ESCC and GC GEJC Treatment | TEVIMBRA® (tislelizumab-jsgr)
TEVIMBRA is a prescription medicine used to treat adults with: cancer of the tube that connects your throat to your stomach (esophageal cancer) TEVIMBRA may be used in combination with chemotherapy that contains platinum as your first treatment when your esophageal cancer: is a type called squamous cell carcinoma, and cannot be removed with surgery or has spread to other parts of the body
- Polymeric micellar paclitaxel, cisplatin, and tislelizumab as . . .
Abstract Objective To evaluate the efficacy and safety of polymeric micellar paclitaxel (Pm-Pac), cisplatin, and tislelizumab as first-line therapy for advanced metastatic esophageal squamous cell carcinoma (ESCC), addressing limitations of conventional paclitaxel regimens related to steroid-induced immunosuppression
|
|
|